Clinical Trials
14 trialsNCT00924196 2026-05-22
Natural History Study of Patients With Neurofibromatosis Type I
National Institutes of Health Clinical Center (CC)
Active not recruiting
NCT06175637 2026-05-13
PEDIA
AstraZeneca
Active not recruiting
NCT06360406 2026-04-30
Real-World Treatment Study of Koselugo (Selumetinib)
AstraZeneca
Recruiting
NCT02544022 2026-04-24
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
National Institutes of Health Clinical Center (CC)
Recruiting
NCT06515860 2026-01-09
NF1-TED
Boston Children's Hospital
Recruiting
NCT06222203 2025-09-26
Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)
National Institutes of Health Clinical Center (CC)
Recruiting
NCT05238909 2025-09-02
Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1
Ann & Robert H Lurie Children's Hospital of Chicago
Enrolling by invitation
NCT02777775 2025-07-24
Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
Corewell Health West
Completed
NCT05683678 2025-04-04
US Selumetinib Registry
Alexion Pharmaceuticals, Inc.
Terminated
NCT06379230 2024-04-23
A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE)
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Unknown
NCT01800032 2021-05-12
PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)
UNC Lineberger Comprehensive Cancer Center
Completed
NCT03027401 2020-10-08
Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics
National Institutes of Health Clinical Center (CC)
Withdrawn
NCT00006435 2020-05-04
Study of Plexiform Neurofibromas in Neurofibromatosis Type 1
National Institutes of Health Clinical Center (CC)
Completed
NCT00340522 2019-12-16
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
National Institutes of Health Clinical Center (CC)
Completed